UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

~~Washington~~WASHINGTON, ~~D.C.~~DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of ~~The~~report ~~Securities~~(Date ~~Exchange~~of ~~Act~~earliest ofevent ~~1934~~reported): March 3, 2026

Date of Report (Date of earliest event reported): February 5, 2026 (February 4, 2026)

STAAR Surgical Company

(Exact ~~name~~Name of ~~registrant~~Registrant as ~~specified~~Specified in ~~its charter~~Charter)

Delaware	0-11634	095-~~11634~~3797439	~~95-3797439~~
(State or other jurisdictionof incorporation)		(CommissionFile Number)	(IRS EmployerIdentification Number)
(State or Other Jurisdictionof Incorporation)	(Commission File Number)	(IRS EmployerIdentification No.)
25510 Commercentre Drive Lake Forest, California			92630
25510 Commercentre DriveLake Forest, California		92630
(Address of principal executive offices)			(Zip Code)
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: 626-303-7902

(Registrant’s telephone number, including area code)

Not Applicable

(Former ~~name~~Name or ~~former~~Former ~~address~~Address, if ~~changed~~Changed ~~since~~Since ~~last~~Last ~~report~~Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written ~~communications~~communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common	STAA	NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of ~~1933~~1 933 (17 CFR §230.405 ~~of this chapter~~) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 ~~of this chapter~~). ☐

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 52.02 ~~Departure~~Results of ~~Directors~~Operations orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

On ~~February~~March 43, 2026, STAAR Surgical Company (the “Company”) ~~entered~~published ~~into~~ a ~~letter~~press ~~agreement~~release ~~with~~reporting ~~Nathaniel~~its ~~Sisitsky,~~financial ~~the~~results ~~Company’s~~for ~~Chief~~the ~~Legal~~quarter ~~Officer~~ and ~~Corporate~~year ~~Secretary~~ended ~~(the~~January ~~“Letter Agreement”)~~2, ~~that provides for Mr. Sisitsky’s termination of employment~~2026, ~~effective~~a ascopy of ~~February~~which 4,is ~~2026~~furnished ~~(the “Separation Date”). Mr. Sisitsky’s termination of employment with the Company will be treated~~ as aExhibit ~~termination by the Company without cause for all purposes~~99.1 ~~The Company also entered into a consulting agreement with Mr. Sisitsky, effective as of the Separation Date, pursuant~~ to ~~which~~this ~~Mr.~~report ~~Sisitsky has agreed to provide consulting services (the “Consulting Services”) related to the performance~~ and ~~transition of responsibilities for the Company’s legal function, through March 13, 2026, or such earlier date as~~ is ~~determined~~incorporated herein by ~~the~~this ~~parties~~reference.

~~The~~Item ~~Letter Agreement provides that, in accordance with Mr~~7.01 Regulation ~~Sisitsky’s~~FD ~~Severance Agreement with the Company, dated as of December 12, 2023 (the “Severance Agreement”), Mr~~Disclosure. Sisitsky will be eligible to receive Base Pay and Employee Benefits (as each such term is defined in the Severance Agreement), including payment of the equivalent of twelve (12) months of Mr. Sisitsky’s base salary and reimbursement of premiums for continued coverage under the Company’s insurance benefit plans for a period of twelve (12) months, in each case subject to the execution and nonrevocation by Mr. Sisitsky of a general release. Pursuant to the Letter Agreement, the Company also agreed that Mr. Sisitsky shall be entitled to receive his 2025 annual bonus, on the same basis and at the same time as it pays 2025 annual bonuses to executives who remain employed on the payment date, as well as the remaining unpaid installment of Mr. Sisitsky’s cash recognition and retention award, in the amount of $75,000. In addition, restricted stock units (“RSUs”) previously granted to Mr. Sisitsky that would otherwise vest in March 2026 (the “March RSUs”) were accelerated and vested as of the Separation Date. All other equity awards granted to Mr. Sisitsky, including outstanding stock options, unvested performance stock units, and unvested RSUs (other than the March RSUs) were forfeited for no consideration as of the Separation Date. Mr. Sisitsky shall receive consulting fees of $8,000 per week as payment for the Consulting Services, and he shall be eligible for a supplemental “Completion Fee” of $10,000 upon the successful completion of the Consulting Services, as determined by the Company.

During a conference call and webcast scheduled to be held at 5:30 p.m. Eastern / 2:30 p.m. Pacific on March 3, 2026, the Company’s Interim Co-Chief Executive Officer, President and Chief Operating Officer and the Company's Interim Co-Chief Executive officer and Chief Financial Officer will discuss the Company’s results for the quarter and year ended January 2, 2026. The Company’s shareholder letter for the conference call is furnished as Exhibit 99.2 to this Current Report.

The information furnished herewith pursuant to Items 2.02 and 7.01 of this Current Report, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in Items 2.02 and 7.01 of this Current Report shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in the filing.

Item 9.01 Financial Statements and Exhibits.


Exhibit No.		Description

99.1		Press release of the Company dated March 3, 2026.

99.2		Shareholder letter of the Company dated March 3, 2026.

104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

STAAR SURGICAL COMPANY


STAAR Surgical Company

March 3, 2026	By:	/s/ DEBORAH ANDREWS
		Deborah Andrews
		Interim Co-Chief Executive Officer and
		Chief Financial Officer

By: /s/ Deborah Andrews

Name: Deborah Andrews

Title: Interim Co-Chief Executive Officer and Chief Financial Officer

Dated: February 4, 2026

Filing Compare · STAAR SURGICAL CO